Chartamentals (Charting + Fundamentals) : #MDT

Price-to-Earnings (P/E): 16.33; Trailing P/E is moderate, below medical device industry average (20–25).
Price-to-Operating Cash Flow: ~10–12 (estimated); Not explicitly provided, reasonable for strong cash flow generation.
Strategic Advantage: Global leader in heart devices, spinal products, insulin pumps, and neuromodulation with innovative pipeline.
Strong Financial Health: $4.58B free cash flow (FY23), low debt-to-equity (0.5), and robust balance sheet.
Fundamental Summary: MDT generates $32.36B revenue (2024, +3.64%), undervalued at $97.46 intrinsic value vs. $84.60 price, faces competition.
Price and Trend Data: $84.60 (Apr 29, 2025), +10.98% 1-year, underperformed S&P 500 by 1.45%.
Price Momentum: +0.66% daily, +0.45% 2-weeks, short-term declining trend.
Moving Averages Indicate: Price above 50-day SMA ($83.58) but below 200-day SMA ($85.70), mixed trend signals.
Relative Strength Index (RSI): 58.25 (14-day), neutral momentum with no overbought/oversold conditions.
Volume and Sentiment: ~4M shares daily average, declining volume with neutral market sentiment.
Technical Summary: Neutral daily signal, mixed indicators (8 buy, 4 sell on moving averages), RSI and MACD reflect balanced momentum.
Conclusion: MDT’s undervaluation and strong cash flow contrast with neutral technicals, indicating stable but cautious market positioning.

this is just educational post. its not buy or sell recommendation. contact your financial advisor before investing.